Wolin named director at Center for Carcinoid and Neuroendocrine Tumors at Mt. Sinai

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Edward Wolin was named director of the Mount Sinai Center for Carcinoid and Neuroendocrine Tumors.

The multidisciplinary center includes Mount Sinai specialists in gastroenterology, surgical oncology, hepatobiliary surgery, thoracic surgery, nuclear medicine, cardiology, medical oncology, radiology, pathology, endocrinology, and nutrition.

Wolin, who will also be a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai, brings a robust research program that includes clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis.

He becomes the second director of the center which was founded by Richard Warner, professor of medicine (gastroenterology), a pioneer in neuroendocrine tumor research and treatment.

Wolin will lead the center along with Michelle Kang Kim, associate professor of medicine (gastroenterology), and who will serve as associate director after previously serving as interim director.

Wolin was most recently director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care. He has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy.

He was previously director of neuroendocrine tumor programs at the University of Kentucky Medical Center and Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the then-largest carcinoid and neuroendocrine tumor programs in the country.

Wolin serves as co-medical director for the Carcinoid Cancer Foundation and on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login